Breaking barriers in haemophilia A care: One‐year real‐world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal

Documenti analoghi

• Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
  di: Robert Klamroth, et al.
  Pubblicazione: (2024)
• The impact of emicizumab on the clinical validation of new therapies for haemophilia A
  di: Cedric Hermans, et al.
  Pubblicazione: (2024)
• Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence
  di: Gili Kenet, et al.
  Pubblicazione: (2024)
• How much prophylaxis is enough in haemophilia?
  di: Manuel Carcao, et al.
  Pubblicazione: (2024)
• Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries
  di: Pier Mannuccio Mannucci, et al.
  Pubblicazione: (2024)